Quarterly ResultMay 13, 2026, 04:14 PM
Acrivon Q1 2026 Net Loss $19.0M; Key Clinical Catalysts Progress
AI Summary
Acrivon Therapeutics reported a net loss of $19.0 million for Q1 2026, a slight improvement from $19.7 million in Q1 2025. The company highlighted significant progress in its clinical programs, including the advancement of the ACR-368 Phase 2b study with an interim analysis planned for H2 2026, and positive initial data from the ACR-2316 Phase 1/2 study showing favorable tolerability and clinical activity. Acrivon also confirmed a cash runway into Q3 2027, supported by $97.7 million in cash and $7.3 million from subsequent equity financing.
Key Highlights
- Q1 2026 net loss was $19.0 million, an improvement from $19.7 million in Q1 2025.
- Cash, cash equivalents, and investments totaled $97.7 million as of March 31, 2026.
- Subsequent equity financing added $7.3 million, extending cash runway into Q3 2027.
- ACR-368 Phase 2b study interim analysis for serous endometrial cancer expected H2 2026.
- ACR-368 showed 52% confirmed ORR in serous EC (N=23) in interim analysis.
- ACR-2316 Phase 1/2 study demonstrated favorable tolerability and clinical activity.
- R&D expenses were $15.2 million in Q1 2026, consistent with prior year.
Price Impact
More from ACRV